ClinicalTrials.gg
CompletedNCT03776812Updated Oct 7, 2025Results posted

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 interventional study of Relacorilant and Nab-paclitaxel in Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by Corcept Therapeutics. Completed at 24 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Ovarian Neoplasms.

Enrollment
2nd of 15
178 · median 43
Started
2019
with 1 other
Phase 2
9 of 15
1 open now
Registered
7th of 15
by date
Lead sponsor
2 of 15
Corcept Therapeutics

Among the 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 7th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

2 of the 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Read the detailed description

Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goals of this study are to evaluate the efficacy of relacorilant either administered daily (continuous) or on the day prior, the day of, and the day after chemotherapy (intermittent) in combination with nab-paclitaxel in the treatment of platinum-resistant ovarian, fallopian tube, or primary peritoneal cancers compared with nab-paclitaxel alone. The safety, pharmacokinetics (PK), and pharmacodynamic profile of relacorilant in combination with nab-paclitaxel will also be assessed.

Eligible patients will be randomized 1:1:1 to one of the following three treatment arms. Patient randomization will be stratified by treatment-free interval from most recent taxane (relapsed within 6 months vs >6 months) and presence of ascites (yes vs no).

  • Arm A (Continuous relacorilant): Relacorilant starting at 100 mg, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
  • Arm B (Intermittent relacorilant): Relacorilant 150 mg, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
  • Arm C (Comparator): Nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

Patients will remain on study treatment until reaching a protocol-defined event of disease progression (PD), experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for progression, subsequent therapies, and survival in the long-term follow-up phase. Patients in Arm C who experience unequivocal PD per RECIST v1.1 will be given the opportunity to receive relacorilant in combination with nab-paclitaxel after discussion with the Medical Monitor (Crossover patients).

03

Conditions studied

  • Recurrent Ovarian Cancer
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Primary Peritoneal Carcinoma

Keywords

  • Glucocorticoid Receptor
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • Nab-paclitaxel
  • Glucocorticoid Receptor Antagonist
  • Relacorilant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated Review Board/Independent Ethics Committee-approved form (ICF) prior to study-specific screening procedures.
  • Female patients aged ≥18 years old at time of consent
  • Histologic diagnosis of high grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer or ovarian carcinosarcoma. Clear cell, mucinous and borderline histologic subtypes are excluded.
  • Received at least 1 with evidence of cancer progression within 6 months after the last dose of platinum-based therapy (ie, having a platinum-free interval of ≤6 months [platinum resistant]), or progressive disease during or immediately after primary platinum-therapy, (ie, platinum ). Patients with primary platinum resistance (progression within 6 months of the last dose of first-line platinum-containing chemotherapy) are considered eligible.

Notes: For the calculation of the platinum-free interval, cancer progression must be defined by clear evidence of progression, such as radiographic progression per v1.1. Calculating the platinum-free interval on the basis of increased Cancer Antigen (CA-125) is not allowed.

  • Measurable or non- by RECIST v1.1:

    • Previously irradiated lesions are not allowed as measurable disease, unless there is documented evidence of progression in the lesions.
    • To be eligible with non-measurable disease, patients must have evaluable disease with CA 125 at least twice the upper limit of reference range (of CA-125 ≥70 U/mL), along with radiographically evaluable disease by computerized tomography (CT)/magnetic resonance imaging (MRI).
  • Availability and consent to provide tumor tissue for biomarker assays (archival or recent ).
  • No more than 4 prior chemotherapeutic or myelosuppressive regimens (not including maintenance therapy such as single-agent bevacizumab or poly (ADP-ribose) polymerase [PARP] inhibitors). Patients with platinum-refractory cancer cannot have had more than 2 prior lines of treatment for refractory disease.
  • Appropriate to treat with nab-paclitaxel, in the opinion of the Investigator.
  • (ECOG) performance status 0 or 1.
  • Adequate organ and bone marrow function meeting the following criteria at the Screening Visit:

    • (ANC) ≥1,500 cells/mm\^3.
    • count ≥100,000/mm\^3.
    • ≥9 g/dL.
    • (AST) or alanine aminotransferase (ALT) ≤2.5 × (ULN) (or ≤5 × ULN in the context of liver ).
    • Total ≤1.5 × ULN.
    • ≥45 mL/min/1.73 m\^2 (measured or estimated).
    • Albumin ≥3 g/dL (≥30 g/L) .
  • If patient has undergone surgery of the gastrointestinal or hepatobiliary tract, adequate absorption as evidenced by: albumin ≥3.0 g/dL, controlled pancreatic insufficiency (if present), and lack of malabsorption.
  • Able to swallow and retain oral medication and does not have uncontrolled emesis.
  • Able to comply with protocol requirements.
  • Negative pregnancy test for patients of . Patients of childbearing potential must use appropriate precautions to avoid pregnancy, defined as of non-childbearing potential (ie, or permanently sterilized) or using highly effective with low user-dependency, for at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest. A woman is postmenopausal if it is more than 12 months since her last menstruation, without an alternative medical cause. Accepted methods of permanent sterilization methods are hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy. Accepted methods of highly effective contraception with low-user-dependency are:

    • An intrauterine device (IUD), provided that the subject has tolerated its use for at least 3 months before the first dose of study medication and undertakes not to have it removed for 1 month after the last dose.
    • Abstinence from heterosexual intercourse, when it is in line with the subject's preferred and usual lifestyle. Periodic abstinence and withdrawal are NOT acceptable.
    • Vasectomized partner provided that the partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success.
    • Oral hormonal contraceptives are NOT permitted.

Exclusion criteria

Exclusion Criteria:

  • toxicity from prior systemic anticancer therapies or radiotherapy that in the opinion of the Investigator has not resolved to Grade 1 or less prior to randomization.
  • Any major surgery within 4 weeks prior to randomization. If subject received major surgery including (curative or palliative surgery), they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  • Treatment with the following prior to randomization:

    • Concurrent treatment with other anticancer therapy including other chemotherapy, immunotherapy, radiotherapy, chemoembolization, targeted therapy, an agent or the non-approved use of a drug or device within 28 days before the first dose of study drug.
    • Hormonal anticancer therapies within 7 days of the first dose of study drug.
    • Systemic, inhaled, or prescription strength topical within 21 days of the first dose of study drug. Short courses (≤5 days) for non-cancer-related reasons are allowed if clinically required (such as prophylaxis for CT).
  • Received radiation to more than 25% of marrow-bearing areas.
  • Toxicities of prior therapies (except alopecia) that have not resolved to National Cancer Institute (NCI-CTCAE) v5.0 ≤Grade 1.
  • Requirement for treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses (eg, rheumatoid arthritis, after organ transplantation).
  • History of severe or severe reaction to either study drug.
  • Peripheral neuropathy from any cause >Grade 1.
  • Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the Screening Visit through at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest.
  • or current chronic/active infection with virus or virus, including:

    • Patients with chronic or active hepatitis B as diagnosed by serologic tests are excluded from the study. In equivocal cases, hepatitis B or C polymerase chain reaction may be performed and must be negative for enrollment.
  • Patient has a clinically significant uncontrolled condition(s) or which in the opinion of the Investigator may confound the results of the trial or interfere with the patient's participation, including but not limited to:

    • Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months before study entry.
    • Uncontrolled hypertension (sustained systolic blood pressure >150 mmHg or diastolic pressure >100 mmHg despite optimal management). Patients will be considered eligible if hypertension is treated and controlled during Screening.
    • Active infection that requires parenteral antibiotics.
    • Bowel obstruction or gastric outlet obstruction.
    • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Untreated parenchymal central nervous system .
  • Any other concurrent cancer or a history of another invasive within the last 3 years that has a likelihood of recurrence of >30% within the next 5 years. Adequately treated non-melanoma skin cancers or non-muscle invasive urothelial cancer or other tumors curatively treated with no evidence of disease are permissible.
  • Are taking a concomitant medication that is a strong inhibitor or inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
  • Concurrent treatment with mifepristone or other glucocorticoid receptor (GR) antagonists.
  • Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
  • Has received a within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Arm A: Continuous Relacorilant Dosing

    Patients will receive relacorilant 100 mg (titrated up to 150 mg after Cycle 1 or 2) once daily in combination with nab-paclitaxel 80 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.

    Drug: Relacorilant · Drug: Nab-paclitaxel

  • Experimental
    Arm B: Intermittent Relacorilant Dosing

    Patients will receive relacorilant 150 mg on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel 80 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.

    Drug: Relacorilant · Drug: Nab-paclitaxel

  • Active comparator
    Arm C: Nab-paclitaxel Comparator

    Patients will receive nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle. Patients initially in Arm C who choose to cross over after disease progression will receive relacorilant 100 mg (titrated up to 150 mg) in combination with nab-paclitaxel 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle after cross over.

    Drug: Relacorilant · Drug: Nab-paclitaxel

Interventions

  • Relacorilant is supplied as capsules for oral dosing.

  • Nab-paclitaxel is administered as IV infusion over 30-40 minutes.

    Also known as: Abraxane

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    To assess time from randomization until the date of first documented progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first.

    Time frame: Baseline and up to 15 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    To assess the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required).

    Time frame: Baseline and up to 15 months

  2. Duration of Response (DOR)

    To assess the time from when response (CR or PR) was first documented to the first objectively documented PD or death (whichever occurs first)

    Time frame: From first documented response up to 12 months

  3. Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG)

    To assess the overall CA-125 response per GCIG criteria. Response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. Patients whose CA-125 levels fall within the reference range are classified as complete responders.

    Time frame: Baseline and up to 15 months

  4. Best Overall Response (BOR)

    To assess the best response (CR, PR, stable disease \[SD\], or PD) recorded from the date of randomization until PD/recurrence (or death)

    Time frame: Baseline and up to 15 months

  5. PFS Rate at 6 and 12 Months

    To assess the proportion of patients who have not progressed according to RECIST v1.1 criteria at 6 and 12 months. Values are Kaplan-Meier estimates of the patients progression-free at the time points specified.

    Time frame: 6 and 12 months

  6. PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

    To assess the time from crossover Baseline (initial PD) until the earliest date of subsequent PD by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever comes first.

    Time frame: Crossover Baseline (Day 50) up to Day 272

  7. ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

    To assess the proportion of patients with measurable disease at the crossover Baseline who attain confirmed CR or PR by RECIST v1.1

    Time frame: Crossover Baseline (Day 50) up to Day 272

  8. DOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

    To assess the time from when the first objective response (CR or PR) in the crossover period to the first objectively documented subsequent PD, or death (whichever occurs first)

    Time frame: From the time of objective response in the crossover period to the time of subsequent PD

  9. BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

    To assess the best overall response (CR, PR, SD, or PD) recorded in the crossover period

    Time frame: Crossover Baseline (Day 50) up to Day 272

  10. Overall Survival (OS)

    To assess the time from randomization to death by any cause.

    Time frame: Up to 31 months

  11. Overall Response According to Combined RECIST v1.1 + GCIG Criteria

    To assess the proportion of patients with measurable disease at Baseline who attain confirmed CR or PR by RECIST v1.1 and GCIG criteria. GCIG response was defined as ≥50% reduction in CA-125 from a pre-treatment sample.

    Time frame: Baseline and up to 15 months

07

Results

Posted Apr 30, 2025

Participant flow

The intent-to-treat (ITT) population included all randomized patients.

Participant flow — Overall Study
MilestoneArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Started586060
Entered crossover0028
Completed000
Not completed586060
Withdrew: Death534956
Withdrew: Withdrawal by subject172
Withdrew: Lost to follow-up110
Withdrew: Did not enter long-term follow-up332

Outcome measures

PrimaryProgression-free Survival (PFS)

To assess time from randomization until the date of first documented progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first.

Time frame:
Baseline and up to 15 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Progression-free Survival (PFS)5.29 (3.84 to 5.55)5.55 (3.68 to 7.20)3.76 (3.52 to 5.36)
Statistical analysis
  • Arm A: Continuous Relacorilant Dosing vs Arm C: Nab-paclitaxel Comparator · Cox proportional hazards model · p = 0.3293 · Hazard ratio (hr): 0.83 · 95% CI 0.56 to 1.22
  • Arm B: Intermittent Relacorilant Dosing vs Arm C: Nab-paclitaxel Comparator · Cox proportional hazards model · p = 0.0384 · Hazard ratio (hr): 0.66 · 95% CI 0.44 to 0.98
SecondaryObjective Response Rate (ORR)

To assess the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required).

Time frame:
Baseline and up to 15 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Objective Response Rate (ORR)192019
SecondaryDuration of Response (DOR)

To assess the time from when response (CR or PR) was first documented to the first objectively documented PD or death (whichever occurs first)

Time frame:
From first documented response up to 12 months
Reported as:
Median · months
Duration of Response (DOR)
monthsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Duration of Response (DOR)3.79 (2.33 to 5.55)5.55 (3.75 to 5.88)3.65 (2.89 to 5.09)
SecondaryCancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG)

To assess the overall CA-125 response per GCIG criteria. Response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. Patients whose CA-125 levels fall within the reference range are classified as complete responders.

Time frame:
Baseline and up to 15 months
Reported as:
Count of participants · Participants
Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG)
ParticipantsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG)323428
SecondaryBest Overall Response (BOR)

To assess the best response (CR, PR, stable disease \[SD\], or PD) recorded from the date of randomization until PD/recurrence (or death)

Time frame:
Baseline and up to 15 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Complete response412
Partial response151917
Stable disease232021
Progressive disease91412
Not evaluable321
SecondaryPFS Rate at 6 and 12 Months

To assess the proportion of patients who have not progressed according to RECIST v1.1 criteria at 6 and 12 months. Values are Kaplan-Meier estimates of the patients progression-free at the time points specified.

Time frame:
6 and 12 months
Reported as:
Number · proportion of patients
PFS Rate at 6 and 12 Months
proportion of patientsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
6 months0.26 (0.15 to 0.38)0.40 (0.28 to 0.53)0.25 (0.15 to 0.36)
12 months0.08 (0.02 to 0.18)0.11 (0.04 to 0.23)0.04 (0.01 to 0.12)
SecondaryPFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

To assess the time from crossover Baseline (initial PD) until the earliest date of subsequent PD by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever comes first.

Time frame:
Crossover Baseline (Day 50) up to Day 272
Reported as:
Median · months
PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
monthsCrossover Patients
PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD2.10 (1.87 to 2.50)
SecondaryORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

To assess the proportion of patients with measurable disease at the crossover Baseline who attain confirmed CR or PR by RECIST v1.1

Time frame:
Crossover Baseline (Day 50) up to Day 272
Reported as:
Count of participants · Participants
ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
ParticipantsCrossover Patients
ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD0
SecondaryDOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

To assess the time from when the first objective response (CR or PR) in the crossover period to the first objectively documented subsequent PD, or death (whichever occurs first)

Time frame:
From the time of objective response in the crossover period to the time of subsequent PD

No measurements were reported for this outcome.

SecondaryBOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD

To assess the best overall response (CR, PR, SD, or PD) recorded in the crossover period

Time frame:
Crossover Baseline (Day 50) up to Day 272
Reported as:
Count of participants · Participants
BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
ParticipantsCrossover Patients
Complete response0
Partial response0
Stable disease3
Progressive disease18
Not evaluable0
SecondaryOverall Survival (OS)

To assess the time from randomization to death by any cause.

Time frame:
Up to 31 months
Reported as:
Median · months
Overall Survival (OS)
monthsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Overall Survival (OS)11.30 (7.52 to 16.39)13.90 (11.07 to 18.43)12.19 (7.72 to 15.28)
SecondaryOverall Response According to Combined RECIST v1.1 + GCIG Criteria

To assess the proportion of patients with measurable disease at Baseline who attain confirmed CR or PR by RECIST v1.1 and GCIG criteria. GCIG response was defined as ≥50% reduction in CA-125 from a pre-treatment sample.

Time frame:
Baseline and up to 15 months
Reported as:
Count of participants · Participants
Overall Response According to Combined RECIST v1.1 + GCIG Criteria
ParticipantsArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Overall Response According to Combined RECIST v1.1 + GCIG Criteria343633

Adverse events

Collected over Up to 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Continuous Relacorilant Dosing53/58 (91.4%)30/57 (52.6%)57/57 (100%)
Arm B: Intermittent Relacorilant Dosing49/60 (81.7%)15/60 (25%)59/60 (98.3%)
Arm C: Nab-paclitaxel Comparator56/60 (93.3%)19/60 (31.7%)60/60 (100%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
Intestinal obstructionGastrointestinal disorders5/572/602/60
Abdominal painGastrointestinal disorders3/571/601/60
Small intestinal obstructionGastrointestinal disorders3/571/601/60
Pleural efffusionRespiratory, thoracic and mediastinal disorders3/571/601/60
ConstipationGastrointestinal disorders2/570/600/60
Large intestinal obstructionGastrointestinal disorders2/570/600/60
VomitingGastrointestinal disorders2/570/600/60
General physical health deteriorationGeneral disorders2/571/600/60
PneumoniaInfections and infestations2/570/601/60
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/571/601/60
Most frequent other events
Showing 10 of 101
Most frequent other events
EventArm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel Comparator
NauseaGastrointestinal disorders41/5730/6027/60
AnaemiaBlood and lymphatic system disorders39/5729/6034/60
VomitingGastrointestinal disorders27/5718/6015/60
Peripheral sensory neuropathyNervous system disorders26/5718/6014/60
ConstipationGastrointestinal disorders25/5719/6017/60
AstheniaGeneral disorders24/5715/6019/60
AlopeciaSkin and subcutaneous tissue disorders21/5722/6024/60
DiarrhoeaGastrointestinal disorders22/5716/6015/60
Abdominal painGastrointestinal disorders21/5716/6020/60
NeutropeniaBlood and lymphatic system disorders20/5711/6020/60

Baseline characteristics

The ITT population included all randomized patients.

Age, Continuous
Age, Continuous(years)Arm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel ComparatorTotal
Mean60.6 ± 8.860.3 ± 9.761.8 ± 8.860.9 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel ComparatorTotal
Female586060178
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel ComparatorTotal
Hispanic or Latino33612
Not Hispanic or Latino535449156
Unknown or Not Reported23510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Continuous Relacorilant DosingArm B: Intermittent Relacorilant DosingArm C: Nab-paclitaxel ComparatorTotal
American Indian or Alaska Native0000
Asian0336
Native Hawaiian or Other Pacific Islander0011
Black or African American0112
White575250159
More than one race0000
Unknown or Not Reported14510
08

Study locations

24 sites
  • Site Reference ID/Investigator #004
    Birmingham, Alabama 35249, United States
  • Site Reference ID/Investigator #038
    Scottsdale, Arizona 85258, United States
  • Site Reference ID/Investigator #032
    Denver, Colorado 80045, United States
  • Site Reference ID/Investigator #001
    Chicago, Illinois 60637, United States
  • Site Reference ID/Investigator #106
    Boston, Massachusetts 02215, United States
  • Site Reference ID/Investigator #128
    Boston, Massachusetts 02215, United States
  • Site Reference ID/Investigator #051
    New York, New York 10065, United States
  • Site Reference ID/Investigator #169
    New York, New York 10065, United States
  • Site Reference ID/Investigator #170
    New York, New York 10065, United States
  • Site Reference ID/Investigator #127
    Pittsburgh, Pennsylvania 15213, United States
  • Site Reference ID/Investigator #135
    Charlottesville, Virginia 22908, United States
  • Site Reference ID/Investigator #121
    Milwaukee, Wisconsin 53226, United States
  • Site Reference ID/Investigator #109
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator #119
    Edegem, 2650, Belgium
  • Site Reference ID/Investigator #108
    Leuven, 3000, Belgium
  • Site Reference ID/Investigator #117
    Toronto, Ontario M4N 3M5, Canada
  • Site Reference ID/Investigator #096
    Montreal, Quebec H2X 0A9, Canada
  • Site Reference ID/Investigator #122
    Milan, 20141, Italy
  • Site Reference ID/Investigator #112
    Naples, 80131, Italy
  • Site Reference ID/Investigator #124
    Roma, 00168, Italy
  • Site Reference ID/Investigator #115
    Barcelona, 08035, Spain
  • Site Reference ID/Investigator #114
    Madrid, 28034, Spain
  • Site Reference ID/Investigator #116
    Madrid, 28034, Spain
  • Site Reference ID/Investigator #113
    Valencia, 46009, Spain
09

References and documents

Publications

  • Zhou Y, Tong F, Jin B, Pan J, Ren N, Ren L, Xu Q. Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study. J Gynecol Oncol. 2025 Jul;36(4):e63. doi: 10.3802/jgo.2025.36.e63. Epub 2025 Feb 20. PubMed 40051286 ↗
  • Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023 Oct 20;41(30):4779-4789. doi: 10.1200/JCO.22.02624. Epub 2023 Jun 26. PubMed 37364223 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Mar 2021, 23 months.

Results were first posted in Apr 2025, 4 years 1 month after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 23 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 17, 2018
StartActual
Apr 5, 2019
Primary completionActual
Mar 16, 2021
CompletionActual
Jul 12, 2023
Results first posted
Apr 30, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03776812
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Apr 5, 2019
Primary completion
Mar 16, 2021
Completion
Jul 12, 2023
Results posted
Apr 30, 2025
Last update
Oct 7, 2025

Study contacts

Sachin Pai, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relacorilant · Albumin-Bound Paclitaxel

Start the discussion